Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.09 USD | -2.62% |
|
-22.10% | -73.00% |
06-20 | UBS Downgrades Zentalis Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $5 From $28 | MT |
06-18 | US Equity Markets Close Up Tuesday Following Less-Than-Expected Retail Sales Growth | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-73.00% | 298M | |
+15.20% | 122B | |
+19.67% | 113B | |
+18.95% | 26.49B | |
-23.86% | 19.4B | |
-19.03% | 16.24B | |
-20.90% | 15.4B | |
-46.14% | 15.15B | |
+63.85% | 14.93B | |
+4.49% | 13.52B |
- Stock Market
- Equities
- ZNTL Stock
- News Zentalis Pharmaceuticals, Inc.
- Morgan Stanley Downgrades Zentalis Pharmaceuticals to Equalweight From Overweight, Cuts PT to $8 From $38; Shares Plunge